UFC Vegas 107 Start Time, Full Fight Card Details!
Ultimate Fighting Championship (UFC) is back after a week off to stage UFC Vegas 107 later TONIGHT (Sat., May 31, 2025) inside UFC Apex in Las Vegas, Nevada. Headlining the ESPN+-streamed event will be a women's Flyweight fight between Erin Blanchfield and Maycee Barber. In the co-main event, Mateusz Gamrot battles fellow Lightweight Ludovít Klein.
What's Hot:
UFC Fight Night: Blanchfield v Barber Weigh-In
Barber didn't do herself any favors in her match toward a potential title shot after she came in heavy for her Flyweight fight against Blanchfield. As a result, 'Future' will have to pay a portion of her fight purse to her opponent, and will not be eligible to win a $50,000 post-fight bonus. Should she win, matchmakers will likely be hesitant to award her a title shot due to the weight mishap, which means she is now at least two more wins away from getting her first-ever UFC title fight. It's a really big miss for Barber, as she is currently on a six-fight win streak and currently holds the No. 5 spot on the official rankings.
UFC Fight Night: Blanchfield v Barber Weigh-In
Blanchfield comes out on top here in more ways than one. Not only does she get a little bump in her paycheck, but she also has the chance to double up on the bonuses should they get 'Fight of the Night.' Furthermore, should she 'humble' Barber in impressive fashion she will shoot to the top of the list of candidates to face Valentina Shevchenko down the road. Blanchfield is currently No. 4 in the rankings and is 7-1 overall inside the Octagon. Natalia Silva is in the top spot to face 'Bullet' next, but Blanchfield has the chance to get next dibs with an impressive win here.
What's Not:
UFC Fight Night: Blanchfield v Barber Weigh-In
Rayanne dos Santos and Alice Ardelean will kick things off in a fight that is a must-win for both. Ardalean has lost her first two fights under the UFC banner, which isn't a good look for a fighter beginning his/her journey on the biggest stage. And dos Santos has suffered that same string of bad luck after going 0-2 to the start of her run. The loser of this fight will likely get cut.
Original Card vs. Actual Card:
UFC Fight Night: Blanchfield v Barber Weigh-In
Oban Elliott was supposed to face Ramiz Brahimaj at this event, but was forced out as a result of visa issues. Brahimaj will now face Billy Ray Goff, who is coming off a loss against Trey Waters. Also, MarQuel Mederos was removed from his bout with Bolaji Oki because of an illness. As a result, Oki will now face newcomer Michael Aswell.
Injuries:
UFC Fight Night: Moreno v Albazi Official Weigh-in
Trevin Giles suffered an injury a day before the UFC Vegas 107 weigh ins, forcing matchmakers to cancel his scheduled fight against Andreas Gustafsson, who was set to make his debut.
New Blood:
UFC Fight Night: Blanchfield v Barber Weigh-In
Michael Aswell agreed to make his UFC debut on three days notice after MarQuel Mederos suffered an illness and was forced out of his fight against Bolaji Oki. Aswell lost his fight on the Contender Series, but bounced back with a win under the Fury FC banner. Now, he has a chance to shine in his UFC debut against Oki, who is 1-1 inside the Octagon and is coming off a loss at the hands of Chris Duncan.
How The 'Prelims' Look:
UFC Fight Night: Blanchfield v Barber Weigh-In
In Lightweight action, Kurt Holobaugh will attempt to get back into the win column after losing in his previous contest against Alexander Hernandez when he goes toe-to-toe against Jordan Leavitt, who is also coming off a loss at the hands of Chase Hopper. Hopper forced Leavitt to tap with a rear-naked choke, his second loss in last three fights. Holobaugh is also 1-2 in his last three trips to the cage.
Advertisement
Allan Nascimento will look to pick up his third straight win when he faces Jafel Filho, who is also eying his third straight win under the UFC banner. Filho tumbled out of the gates in his UFC debut, losing to Muhammad Mokaev. He recovered nicely by winning back-to-back fights against Daniel Barez and Ode Osbourne. As for Nascimento, he did the same after losing his first fight under the UFC banner against Tagir Ulanbekov, defeating Jake Hadley and Carlos Hernandez in consecutive contests.
Who Needs A Win Badly:
UFC Fight Night: Blanchfield v Barber Weigh-In
In men's Middleweight action, Dusko Todorovic will face Zachary Reese. Todorovic is currently on a two-fight losing streak and is just 3-5 under the UFC banner. He is definitely on the chopping block with a run like that, and a third straight defeat at the hands of Reese could prove to be the nail in the coffin of his UFC career. As for Reese, he had his two-fight win streak snapped by Azamat Bekoev, who knocked him out in the very first round (see it again here).
Interest Level: 5/10
UFC Fight Night: Blanchfield v Barber Weigh-In
In the co-main event, Mateusz Gamrot will attempt to get back in the win column when he goes up against Ludovít Klein. Gamrot had his three-fight win streak snapped his last time out at the hands of Dan Hooker, who walked away with a close split-decision win at UFC 305. Prior to that defeat, Gamrot was 7-2 inside the Octagon, scoring big wins over Arman Tsarukyan, Rafael dos Anjos and Rafael Fiziev, just to name a few. He is currently ranked No. 7, but a win over Klein could get him closer to the Top 5. Speaking of Klein, he has quietly been on a hot streak since 2022, going 6-0-1 during that span. That said, it's not good enough to get him a spot in the Top 15, but a victory of Gamrot will be.
Advertisement
In what proved to be a disastrous weigh-in, Ketlen Vieira had trouble cutting down to the allowed 136 weight limit for her Bantamweight showdown against Macy Chiasson, so the fight was changed to take place at Featherweight. It's not a good look for Vieira, who is coming off a loss to Kayla Harrison at UFC 307. As for Chiasson, she is currently on a two-fight win streak and one more win could move her into the Top 3.
UFC Fight Night: Blanchfield v Barber Weigh-In
Bruno Lopes got off to a great start to his UFC career by defeating Magomed Gadzhiyasulov in his promotional debut bout. Winner of three in a row, 'Brunao' is out to collect lucky win number four as he goes up against Dustin Jacoby, who snapped his two-fight skid by defeating Vitor Petrino via knockout in Dec. 2024 (highlights).
Full UFC Vegas 107 Fight Card:
UFC Vegas 107 Main Event On ESPN/ESPN+:
125 lbs.: Erin Blanchfield vs. Maycee Barber
UFC Vegas 107 Main Card on ESPN/ESPN+ (9 p.m. ET):
155 lbs.: Mateusz Gamrot vs. Ludovít Klein
170 lbs.: Billy Ray Goff vs. Ramiz Brahimaj
205 lbs.: Dustin Jacoby vs. Bruno Lopes
145 lbs.: Ketlen Vieira vs. Macy Chiasson (changed to featherweight)
185 lbs.: Zach Reese vs. Dusko Todorovic
UFC Vegas 107 Prelims Card on ESPN+ (6:30 p.m. ET):
125 lbs.: Jafel Filho vs. Allan Nascimento
155 lbs.: Kurt Holobaugh vs. Jordan Leavitt
180 lbs.: Trevin Giles vs. Andreas Gustafsson — CANCELED (details here)
155 lbs.: Bolaji Oki vs. Michael Aswell (not MarQuel Mederos)
115 lbs.: Rayanne dos Santos vs. Alice Ardelean
*Fight card, bout order and amount of fights remain subject to change.*
MMAmania.com will deliver LIVE round-by-round, blow-by-blow coverage of the entire UFC Vegas 107 fight card RIGHT HERE, starting with the ESPN+ preliminary card bouts at 6:30 p.m. ET, followed by the remaining main card balance on ESPN/ESPN+ at 9 p.m. ET.
Advertisement
To check out the latest and greatest UFC Vegas 107 news and notes be sure to hit up our comprehensive event archives here and here. For the updated and finalized 'Blanchfield vs. Barber' fight card and ESPN/ESPN+ lineup click here.
More from mmamania.com:
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
16 minutes ago
- Yahoo
Spinning Back Clique LIVE (noon ET): Blanchfield-Barber canceled, UFC 316 preview, more
Check out this week's "Spinning Back Clique," MMA Junkie's weekly live show that takes a spin through the biggest topics in mixed martial arts. This week's panel of Brian "Goze" Garcia, Mike Bohn and Danny Segura will join host "Gorgeous" George Garcia live at noon ET (9 a.m. PT) to discuss and debate the following topics: Advertisement We start off the show with a recap of what happened (and didn't happen) Saturday at UFC on ESPN 68. Most notably, we'll discuss the bizarre, last-minute cancellation of the main event women's flyweight bout between Erin Blanchfield and Maycee Barber. According to the UFC, Barber wasn't allowed to fight due to medical issues, thus canceling her fight literally when she was supposed to walk to the octagon. We'll take a look at the good and the bad major headlines this past week. From UFC legend B.J. Penn's multiple arrests, to Noche UFC moving from Guadalajara to San Antonio and some recent bookings, we react to it all. We preview all the action at UFC 316, which goes down Saturday in Newark, N.J. Can Sean O'Malley settle the score with bantamweight champion Merab Dvalishvili? Will Kayla Harrison take the women's bantamweight title from Julianna Peña and lure Amanda Nunes out of retirement? We break it all down. This article originally appeared on MMA Junkie: Spinning Back Clique: Blanchfield-Barber canceled, UFC 316 preview
Forbes
17 minutes ago
- Forbes
Employers Reluctant To Cover Obesity Meds, Lower Costs May Change This
A new survey report from the International Foundation of Employee Benefit Plans shows continued reluctance by United States employers to cover glucagon-like peptide-1 drugs for weight loss. Going forward, however, lower net costs may induce better coverage by employers. Makers of GLP-1s for obesity are offering an array of discounts, some to insurers, others directly to patients. The IFEBP first conducted the survey in Oct. 2023 and again in May 2024. In the latest survey released ten days ago, employers revealed that 55% of them provide coverage of GLP-1s for diabetes only, while only 36% provide coverage for both diabetes and weight loss. And of those employers currently offering GLP-1 drug coverage solely for diabetes, just 17% are considering reimbursement of drugs for weight loss. Broadly speaking, the survey responses demonstrate that a large number of employers are still unwilling to reimburse GLP-1s for obesity. The weight loss therapeutics activate the body's receptors for GLP-1 on its own or in combination with GIP. When released by the gut, these natural hormones increase insulin delivery, suppress appetite, slow stomach emptying and increase the feeling of fullness. Perhaps what's driving continued reluctance to cover these products for weight loss is the overall impact that GLP-1s have on employers' pharmacy budgets. GLP-1 drugs used for obesity account for an average of 10.5% of total annual claims in the 2025 survey. In parts of the traditional health plans' market, we observe that some insurers are reconsidering their coverage of GLP-1s. Blue Cross Blue Shield, for example, just announced a reversal in its policy in which some plans offered coverage of GLP-1s for obesity. Starting in January 2026, BCBS will no longer cover these medicines for weight loss across the insurer's standard plans. At the same time, however, the large insurer Cigna announced it will begin capping out-of-pocket costs at $200 per month, starting next month, for patients using the obesity drugs Wegovy (semaglutide) and Zepbound (tirzepatide) through an add-on to its pharmacy benefit management plans. This is aimed at encouraging more employers to offer coverage of the drugs. It's unknown what the net cost to Cigna will be for the medicines. But presumably, the insurer has been able to reach a deal that's favorable financially, meaning a substantial reduction in net costs. It's possible in future that employers decide to revisit their coverage decisions if net costs decrease sufficiently, combined with more data showing the benefits of weight loss drugs when taken consistently and in conjunction with an appropriate dietary and exercise regimen. Also, the pharmaceutical firm Novo Nordisk announced last month a new partnership with CVS Caremark, the nation's largest pharmacy benefit manager, which grants coverage of Wegovy over its competitor Zepbound for customers who are insured for obesity medications. It's presumed that CVS was able to negotiate sizable rebates for Wegovy. CVS Caremark said that for insured patients, starting this July, Wegovy and Saxenda (liraglutide) will be the preferred GLP-1 medicines on its largest commercial formularies. This implies fewer access restrictions such as prior authorization, but also lower patient cost-sharing. It's unknown precisely what this means in terms of out-of-pocket costs for patients. But most patients with coverage for obesity drugs have monthly cost-sharing under $100. The arrangements reached by Cigna and CVS could help bring down net prices for employers for popular weight loss medicines. And at the same time, under the Inflation Reduction Act, the federal government is negotiating the prices of the GLP-1s Ozempic (semaglutide) and Wegovy. So-called maximum fair prices will be publicly posted in early 2026. These could reflect even steeper discounts. In addition to what payers are doing, Novo Nordisk is pursuing a direct-to-patient strategy to regain market share it has lost to drug maker Eli Lilly in the lucrative obesity drug market. Here, Novo Nordisk struck a deal in which CVS pharmacy will offer Wegovy for $499 a month for cash-paying customers who aren't insured for the medication. Since the Food and Drug Administration removed the active ingredients semaglutide and tirzepatide from its shortage list, the business model of selling directly at a considerable discount to the consumer has become popular for the two main manufacturers of obesity drugs. In 2024, Eli Lilly adopted a direct-to-consumer strategy for Zepbound, among other products, with its LillyDirect program. This service includes a DTC pharmacy and a referral network of in-person and telehealth clinicians. LillyDirect allows uninsured or underinsured individuals not on Medicaid or Medicare to purchase Zepbound product directly after obtaining the requisite prescription from their doctor. The firm recently extended the range of Zepbound products available through LillyDirect by adding high-dose vials at $499. Rival Novo Nordisk also launched a DTC option, NovoCare Pharmacy, two months ago. Patients not insured in the public sector who wish to have access to Wegovy can acquire the drug for an out-of-pocket cost of $499 per month, provided they have a prescription and make use of a designated specialty pharmacy. And, since the end of April, customers also pay a $499 monthly subscription when they obtain Wegovy from Ro and LifeMD, and $599 at Hims & Hers. While employers aren't yet reimbursing weight loss drugs en masse, significantly reduced net costs could affect their future coverage decisions.
E&E News
18 minutes ago
- E&E News
Meet the youth challenging Trump on climate
Eva Lighthiser, 19, lives in Livingston, Montana, and is accustomed to milelong coal trains rumbling through town and blowing coal dust across the city. In 2023, she was a plaintiff in a youth-led lawsuit that sought to force her state to tackle climate change. Now, she's the lead challenger in Lighthiser v. Trump, a new climate lawsuit that accuses President Donald Trump of violating the Constitution by issuing a trio of executive orders that fast track fossil fuel development. 'Every place is going to be affected by this administration and it's very concerning to see what that will look like moving forward,' Lighthiser said in an interview. Advertisement The case, filed last week in the U.S. District Court for the District of Montana, argues that Trump's executive orders will worsen climate change and increase health dangers by declaring a 'national energy emergency' and directing the government to 'unleash American energy.'
